Research at Kumquat Biosciences Inc. has led to the development of Hetero-atom containing compounds described as tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and (PTPN2; TCPTP) inhibitors and reported to be useful for the treatment of cancer.
The Institute for Drug Research has patented pyrrolidine antiviral compounds acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors.
TYK Medicines Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising cereblon (CRBN) binding moieties covalently linked to EGFR (HER1; erbB1) binding moieties reported to be useful for the treatment of cancer, infections, cardiovascular, immunological, inflammatory and metabolic diseases.
Wuhan Zhongcheng Health Bio-Pharm Technology Co. Ltd. has disclosed aromatic amine compounds acting as Bcr-Abl (Bcr-Abl1) kinase inhibitors reported to be useful for the treatment of neurodegeneration, motor neuron disease, muscular dystrophy, autoimmune disease and inflammation, viral infection, prion infection and cancer.
Researchers from INSERM, Samsara Sciences Inc., Sorbonne University and Université Paris Cité have described autophagy inducers reported to be useful for the treatment of cancer, age-related disorders and viral infections.
Janssen Pharmaceutica NV has divulged macrocyclic compounds acting as induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors reported to be useful for the treatment of cancer.
Researchers at Hitgen Ltd. and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. have identified proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1) targeting moiety via linker.
Researchers from F. Hoffmann-La Roche Ltd., Hoffmann-La Roche Inc. and Icagen Inc. have disclosed heteroaryl-urea compounds acting as potassium voltage-gated channel subfamily KQT member 2 (KCNQ2; Kv7.2) activators reported to be useful for the treatment of autism spectrum...
MD Biopharm Co. Ltd. has described protein-glutamine γ-glutamyltransferase 2 (TGM2) inhibitors reported to be useful for the treatment of cancer, celiac disease, neurological, inflammatory and cardiovascular disorders.
RSS